Farah Eaton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Farah Eaton has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- John Reyes Ussher
Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada
3 shared publications - Christina T. Saed
Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada
2 shared publications - Dawn Bowles
Department of Surgery, Duke University, Durham, NC 27710, USA
2 shared publications - Evangelos D. Michelakis
Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
2 shared publications - Gopinath Sutendra
Department of Medicine, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB, Canada
2 shared publications - Jason R. B. Dyck
University of Alberta
2 shared publications
Latest Publications
- Open Access
- 20 October 2026
- Published by Elsevier in Canadian Journal of Diabetes
Ovariectomy abolishes cardioprotection against diastolic dysfunction and impairs cardiac glucose oxidation in female mice with type 2 diabetes
- 20 October 2026
- Published by Elsevier in Canadian Journal of Diabetes
Open AccessOvariectomy abolishes cardioprotection against diastolic dysfunction and impairs cardiac glucose oxidation in female mice with type 2 diabetes
- 15 April 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (845) , eadz7727
Selective translation of ZNF281 as part of the integrated stress response system has therapeutic relevance for cardio-oncology
A well-recognized attribute of several common and standard cancer therapeutics is the development of cardiotoxicity. Although many anticancer agents appear to target a relatively select and distinct signaling pathway in the tumor, we hypothesized that several different classes of chemotherapeutics may converge into one central stress-sensing system in terminally differentiated cardiomyocytes. Here, we showed that anticancer intercalating/alkylating agents, tyrosine kinase inhibitors, or receptor inhibitors can converge and increase the selective and preferential translation of the transcription factor ZNF281 in cardiomyocytes. Cardiomyocyte-specific ZNF281-deficient mice were completely resistant to anthracycline-mediated cardiotoxicity (AIC), whereas cardiomyocyte-specific ZNF281-overexpressing mice had clinical features of cardiotoxicity. Inhibition of ZNF281 with ZIM, a first-of-its-kind small-molecule drug, completely prevented AIC, enhanced lung tumor regression, and prevented lung metastasis in a metastatic melanoma model. Induction of ZNF281, along with its downstream signaling cascade, was preserved in myocardial tissues from patients with AIC, indicating the translational potential of ZNF281 inhibition in alleviating cardiotoxicity resulting from chemotherapeutic treatments.
- 15 April 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (845) , eadz7727
Selective translation of ZNF281 as part of the integrated stress response system has therapeutic relevance for cardio-oncology
A well-recognized attribute of several common and standard cancer therapeutics is the development of cardiotoxicity. Although many anticancer agents appear to target a relatively select and distinct signaling pathway in the tumor, we hypothesized that several different classes of chemotherapeutics may converge into one central stress-sensing system in terminally differentiated cardiomyocytes. Here, we showed that anticancer intercalating/alkylating agents, tyrosine kinase inhibitors, or receptor inhibitors can converge and increase the selective and preferential translation of the transcription factor ZNF281 in cardiomyocytes. Cardiomyocyte-specific ZNF281-deficient mice were completely resistant to anthracycline-mediated cardiotoxicity (AIC), whereas cardiomyocyte-specific ZNF281-overexpressing mice had clinical features of cardiotoxicity. Inhibition of ZNF281 with ZIM, a first-of-its-kind small-molecule drug, completely prevented AIC, enhanced lung tumor regression, and prevented lung metastasis in a metastatic melanoma model. Induction of ZNF281, along with its downstream signaling cascade, was preserved in myocardial tissues from patients with AIC, indicating the translational potential of ZNF281 inhibition in alleviating cardiotoxicity resulting from chemotherapeutic treatments.
- Open Access
- 2 April 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (7) , e032697
Pharmacological Inhibition of Succinyl Coenzyme A:3‐Ketoacid Coenzyme A Transferase Alleviates the Progression of Diabetic Cardiomyopathy
- 2 April 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (7) , e032697
Open AccessPharmacological Inhibition of Succinyl Coenzyme A:3‐Ketoacid Coenzyme A Transferase Alleviates the Progression of Diabetic Cardiomyopathy
- 2 November 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 14 (669) , eabm3565
TRIM35-mediated degradation of nuclear PKM2 destabilizes GATA4/6 and induces P53 in cardiomyocytes to promote heart failure
Pyruvate kinase M2 (PKM2) is a glycolytic enzyme that translocates to the nucleus to regulate transcription factors in different tissues or pathologic states. Although studied extensively in cancer, its biological role in the heart remains unresolved. PKM1 is more abundant than the PKM2 isoform in cardiomyocytes, and thus, we speculated that PKM2 is not genetically redundant to PKM1 and may be critical in regulating cardiomyocyte-specific transcription factors important for cardiac survival. Here, we showed that nuclear PKM2 ( S37 P-PKM2) in cardiomyocytes interacts with prosurvival and proapoptotic transcription factors, including GATA4, GATA6, and P53. Cardiomyocyte-specific PKM2-deficient mice ( Pkm2 Mut Cre + ) developed age-dependent dilated cardiac dysfunction and had decreased amounts of GATA4 and GATA6 (GATA4/6) but increased amounts of P53 compared to Control Cre + hearts. Nuclear PKM2 prevented caspase-1–dependent cleavage and degradation of GATA4/6 while also providing a molecular platform for MDM2-mediated reduction of P53. In a preclinical heart failure mouse model, nuclear PKM2 and GATA4/6 were decreased, whereas P53 was increased in cardiomyocytes. Loss of nuclear PKM2 was ubiquitination dependent and associated with the induction of the E3 ubiquitin ligase TRIM35. In mice, cardiomyocyte-specific TRIM35 overexpression resulted in decreased S37 P-PKM2 and GATA4/6 along with increased P53 in cardiomyocytes compared to littermate controls and similar cardiac dysfunction to Pkm2 Mut Cre + mice. In patients with dilated left ventricles, increase in TRIM35 was associated with decreased S37 P-PKM2 and GATA4/6 and increased P53. This study supports a previously unrecognized role for PKM2 as a molecular platform that mediates cell signaling events essential for cardiac survival.
- 2 November 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 14 (669) , eabm3565
TRIM35-mediated degradation of nuclear PKM2 destabilizes GATA4/6 and induces P53 in cardiomyocytes to promote heart failure
Pyruvate kinase M2 (PKM2) is a glycolytic enzyme that translocates to the nucleus to regulate transcription factors in different tissues or pathologic states. Although studied extensively in cancer, its biological role in the heart remains unresolved. PKM1 is more abundant than the PKM2 isoform in cardiomyocytes, and thus, we speculated that PKM2 is not genetically redundant to PKM1 and may be critical in regulating cardiomyocyte-specific transcription factors important for cardiac survival. Here, we showed that nuclear PKM2 ( S37 P-PKM2) in cardiomyocytes interacts with prosurvival and proapoptotic transcription factors, including GATA4, GATA6, and P53. Cardiomyocyte-specific PKM2-deficient mice ( Pkm2 Mut Cre + ) developed age-dependent dilated cardiac dysfunction and had decreased amounts of GATA4 and GATA6 (GATA4/6) but increased amounts of P53 compared to Control Cre + hearts. Nuclear PKM2 prevented caspase-1–dependent cleavage and degradation of GATA4/6 while also providing a molecular platform for MDM2-mediated reduction of P53. In a preclinical heart failure mouse model, nuclear PKM2 and GATA4/6 were decreased, whereas P53 was increased in cardiomyocytes. Loss of nuclear PKM2 was ubiquitination dependent and associated with the induction of the E3 ubiquitin ligase TRIM35. In mice, cardiomyocyte-specific TRIM35 overexpression resulted in decreased S37 P-PKM2 and GATA4/6 along with increased P53 in cardiomyocytes compared to littermate controls and similar cardiac dysfunction to Pkm2 Mut Cre + mice. In patients with dilated left ventricles, increase in TRIM35 was associated with decreased S37 P-PKM2 and GATA4/6 and increased P53. This study supports a previously unrecognized role for PKM2 as a molecular platform that mediates cell signaling events essential for cardiac survival.
- 15 May 2022
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 205 (10) , 1186-1201
Pulmonary and Neurologic Effects of Mesenchymal Stromal Cell Extracellular Vesicles in a Multifactorial Lung Injury Model
Rationale: Bronchopulmonary dysplasia, a chronic respiratory condition originating from preterm birth, is associated with abnormal neurodevelopment. Currently, there is an absence of effective therapies for bronchopulmonary dysplasia and its associated brain injury. In preclinical trials, mesenchymal stromal cell therapies demonstrate promise as a therapeutic alternative for bronchopulmonary dysplasia. Objectives: To investigate whether a multifactorial neonatal mouse model of lung injury perturbs neural progenitor cell function and to assess the ability of human umbilical cord–derived mesenchymal stromal cell extracellular vesicles to mitigate pulmonary and neurologic injury. Methods: Mice at Postnatal Day 7 or 8 were injected intraperitoneally with LPS and ventilated with 40% oxygen at Postnatal Day 9 or 10 for 8 hours. Treated animals received umbilical cord–mesenchymal stromal cell–derived extracellular vesicles intratracheally preceding ventilation. Lung morphology, vascularity, and inflammation were quantified. Neural progenitor cells were isolated from the subventricular zone and hippocampus and assessed for self-renewal, in vitro differentiation ability, and transcriptional profiles. Measurements and Main Results: The multifactorial lung injury model produced alveolar and vascular rarefaction mimicking bronchopulmonary dysplasia. Neural progenitor cells from lung injury mice showed reduced neurosphere and oligodendrocyte formation, as well as inflammatory transcriptional signatures. Mice treated with mesenchymal stromal cell extracellular vesicles showed significant improvement in lung architecture, vessel formation, and inflammatory modulation. In addition, we observed significantly increased in vitro neurosphere formation and altered neural progenitor cell transcriptional signatures. Conclusions: Our multifactorial lung injury model impairs neural progenitor cell function. Observed pulmonary and neurologic alterations are mitigated by intratracheal treatment with mesenchymal stromal cell–derived extracellular vesicles.
- 15 May 2022
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 205 (10) , 1186-1201
Pulmonary and Neurologic Effects of Mesenchymal Stromal Cell Extracellular Vesicles in a Multifactorial Lung Injury Model
Rationale: Bronchopulmonary dysplasia, a chronic respiratory condition originating from preterm birth, is associated with abnormal neurodevelopment. Currently, there is an absence of effective therapies for bronchopulmonary dysplasia and its associated brain injury. In preclinical trials, mesenchymal stromal cell therapies demonstrate promise as a therapeutic alternative for bronchopulmonary dysplasia. Objectives: To investigate whether a multifactorial neonatal mouse model of lung injury perturbs neural progenitor cell function and to assess the ability of human umbilical cord–derived mesenchymal stromal cell extracellular vesicles to mitigate pulmonary and neurologic injury. Methods: Mice at Postnatal Day 7 or 8 were injected intraperitoneally with LPS and ventilated with 40% oxygen at Postnatal Day 9 or 10 for 8 hours. Treated animals received umbilical cord–mesenchymal stromal cell–derived extracellular vesicles intratracheally preceding ventilation. Lung morphology, vascularity, and inflammation were quantified. Neural progenitor cells were isolated from the subventricular zone and hippocampus and assessed for self-renewal, in vitro differentiation ability, and transcriptional profiles. Measurements and Main Results: The multifactorial lung injury model produced alveolar and vascular rarefaction mimicking bronchopulmonary dysplasia. Neural progenitor cells from lung injury mice showed reduced neurosphere and oligodendrocyte formation, as well as inflammatory transcriptional signatures. Mice treated with mesenchymal stromal cell extracellular vesicles showed significant improvement in lung architecture, vessel formation, and inflammatory modulation. In addition, we observed significantly increased in vitro neurosphere formation and altered neural progenitor cell transcriptional signatures. Conclusions: Our multifactorial lung injury model impairs neural progenitor cell function. Observed pulmonary and neurologic alterations are mitigated by intratracheal treatment with mesenchymal stromal cell–derived extracellular vesicles.